FDA Approves Expanded Label for Teva Parkinson’s Drug
Teva Pharmaceutical Industries Ltd. announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Azilect (rasagiline tablets) from monotherapy and adjunct to levodopa (LD) to now include adjunct to dopamine agonists (DAs). The new indication reflects that Azilect can be used alone or in combination with other Parkinson’s disease (PD) medications. The approval reinforces the growing clinical evidence demonstrating the benefit of Azilect across all stages of PD.
http://www.dddmag.com/news/2014/06/f...4&location=top |
All times are GMT -5. The time now is 09:37 AM. |
Powered by vBulletin Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.